Last reviewed · How we verify
corticosteroid and azathioprine
Corticosteroids suppress the immune system by inhibiting the production of inflammatory cytokines, while azathioprine is an immunosuppressive medication that interferes with DNA synthesis.
Corticosteroids suppress the immune system by inhibiting the production of inflammatory cytokines, while azathioprine is an immunosuppressive medication that interferes with DNA synthesis. Used for Treatment of rheumatoid arthritis, lupus, and other autoimmune diseases.
At a glance
| Generic name | corticosteroid and azathioprine |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Corticosteroid and immunosuppressant |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids work by binding to glucocorticoid receptors, which then translocate to the nucleus and inhibit the transcription of inflammatory genes. Azathioprine, on the other hand, is a purine synthesis inhibitor that prevents the proliferation of T and B lymphocytes, thereby reducing the immune response.
Approved indications
- Treatment of rheumatoid arthritis, lupus, and other autoimmune diseases
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Headache
- Fatigue
- Infection
- Anemia
- Thrombocytopenia
- Leukopenia
Key clinical trials
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) (PHASE3)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- Rituximab in Eosinophilic Granulomatosis With Polyangiitis (PHASE3)
- Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis (NA)
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (PHASE2)
- Efficacy Study of Two Treatments in the Remission of Vasculitis (PHASE3)
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: